Another thing. Two drugs with EUA are below our statistical grade for both safety and efficacy. How were they given the green EUA light? FDA as well has given approvals for other drugs before COVID with less that significant values in the past. So they rushed to rubber stamp their BP buddies and now pull back when a real working solution is presented. They are going to have a tough time not giving an EUA. Not being fair and balanced as history has shown for decades and now with COVID is appalling, not going unnoticed by physicians to politician to lay people. Whether we unblind and take that aggressive approach or stay the course with the hand dealt, we will get an approval one way or the other. The game they played with the BLA is what they do best. Should there be a sudden change of leadership at the FDA and CDC in a few short weeks, the playing field will be a bit more level. The risk vs reward is based on leronlimab approval. Whether sooner or later, whether only COVID or HIV or both. Later being December of Q1 2021 is not long off. Sooner could be the Philippines or EUA.
IMO we will get approval most likely as a combo therapy so to hold up a half baked remdesivir. Call it a gentleman's agreement or truce pact.
News 
Market Data 
Discover 
